Medication adherence for patient support

Conditions

Specialty: Primary Care, Primary sub-specialty: Diabetes

Aikaterini Kassavou, Venus Mirzaei, James Brimicombe, Simon Edwards, Efthalia Massou et al. (8 authors)

Journal of Medical Internet Research2020-02-0146 citations

Development and piloting of a highly tailored digital intervention to support adherence to antihypertensive medications as an adjunct to primary care consultations.

Aikaterini Kassavou, Vikki Houghton, Simon Edwards, James Brimicombe, Stephen Sutton

Apollo (University of Cambridge)2019-01-06

10.17863/cam.35636

Development and piloting of a highly tailored digital intervention to support adherence to antihypertensive medications as an adjunct to primary care consultations

Aikaterini Kassavou, Vikki Houghton, Simon Edwards, James Brimicombe, Stephen Sutton

BMJ Open2019-01-0128 citations

10.1136/bmjopen-2018-024121

Interventions

Participants will be randomised to the intervention (N=60) or comparator (n=40) group stratified by age, gender, practice and disease condition using a secure, computer random number generator:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with primary diagnosis of T2DM and/or hypertension 2. Poorly controlled hypertension and/or T2DM, as indicated by clinical measures or gaps in ordering or filling repeat prescriptions 3. 18 years old and above

Exclusion criteria

Exclusion criteria: Patients will be excluded if they: 1. Have a hearing impairment (hearing spectrum lower than 50Hz-20kHz) or a speaking impairment 2. Have a diagnosis of dementia, aphasia or other cognitive difficulties that could affect study participation 3. Have had a recent severe life-threatening event or are under treatment for another long-term condition (e.g. cancer) 4. Receive kidney dialysis 5. Are participating in another study 6. Plan to move from the area in the next 6 months

Design outcomes

Primary

Measure	Time frame
1. Medication adherence: 1.1. Self-reported medication adherence, measured using two items at baseline and 3 months 1.2. Objectively measured medication adherence, collected by electronic monitoring devices (MEMS container caps that record the date and time of each opening) at 3 months 1.3. Objectively measured refill medication data, collected using records from practice or pharmacy dispensary at baseline and 3 months 2. Blood pressure, collected using an electronic sphygmomanometer or other blood pressure monitor devices available in each practice at 3 months 3. Glucose levels (HbA1c), collected using venous blood samples by practice nurse at 3 months	—

Measure

Time frame

1. Medication adherence: 1.1. Self-reported medication adherence, measured using two items at baseline and 3 months 1.2. Objectively measured medication adherence, collected by electronic monitoring devices (MEMS container caps that record the date and time of each opening) at 3 months 1.3. Objectively measured refill medication data, collected using records from practice or pharmacy dispensary at baseline and 3 months 2. Blood pressure, collected using an electronic sphygmomanometer or other blood pressure monitor devices available in each practice at 3 months 3. Glucose levels (HbA1c), collected using venous blood samples by practice nurse at 3 months

—

Secondary

Measure	Time frame
Quality of life, measured using the self-reported EQ-5D-5L at baseline and 3 months	—

Countries

England, United Kingdom

Contacts

Public ContactKaterina Kassavou

kk532@medschl.cam.ac.uk+44 (0)1223 330 456

Outcome results

None listed